Arca Biopharma Stock Current Asset
ARCA Biopharma fundamentals help investors to digest information that contributes to ARCA Biopharma's financial success or failures. It also enables traders to predict the movement of ARCA Stock. The fundamental analysis module provides a way to measure ARCA Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ARCA Biopharma stock.
ARCA |
ARCA Biopharma Company Current Asset Analysis
ARCA Biopharma's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current ARCA Biopharma Current Asset | 5.88 M |
Most of ARCA Biopharma's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ARCA Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
CompetitionIn accordance with the recently published financial statements, ARCA Biopharma has a Current Asset of 5.88 M. This is 99.73% lower than that of the Biotechnology sector and 99.45% lower than that of the Health Care industry. The current asset for all United States stocks is 99.94% higher than that of the company.
ARCA Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ARCA Biopharma's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ARCA Biopharma could also be used in its relative valuation, which is a method of valuing ARCA Biopharma by comparing valuation metrics of similar companies.ARCA Biopharma is currently under evaluation in current asset category among its peers.
ARCA Fundamentals
| Return On Equity | -0.2 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | 393.23 M | |||
| Shares Outstanding | 14.51 M | |||
| Shares Owned By Insiders | 1.20 % | |||
| Shares Owned By Institutions | 98.80 % | |||
| Number Of Shares Shorted | 4.99 M | |||
| Price To Earning | (0.63) X | |||
| Price To Book | 13.09 X | |||
| EBITDA | (7.3 M) | |||
| Net Income | (5.34 M) | |||
| Cash And Equivalents | 46.44 M | |||
| Cash Per Share | 3.22 X | |||
| Total Debt | 280 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 16.97 X | |||
| Book Value Per Share | 2.25 X | |||
| Cash Flow From Operations | (5.01 M) | |||
| Short Ratio | 62.38 X | |||
| Earnings Per Share | (5.88) X | |||
| Target Price | 7.0 | |||
| Beta | 0.9 | |||
| Market Capitalization | 34.82 M | |||
| Total Asset | 37.86 M | |||
| Retained Earnings | (188.74 M) | |||
| Working Capital | 36.95 M | |||
| Current Asset | 5.88 M | |||
| Current Liabilities | 26.61 M | |||
| Annual Yield | 8.27 % | |||
| Net Asset | 37.86 M |
About ARCA Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ARCA Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ARCA Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ARCA Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ARCA Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARCA Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against ARCA Stock
The ability to find closely correlated positions to ARCA Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARCA Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARCA Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARCA Biopharma to buy it.
The correlation of ARCA Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARCA Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARCA Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARCA Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in ARCA Stock
If you are still planning to invest in ARCA Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ARCA Biopharma's history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |